viewZelira Therapeutics Ltd

Three medical cannabis companies in focus at Proactive’s webinar on August 11

The select group of companies will join Proactive’s John Phillips at the virtual investor conference on Tuesday, August 11 at 12pm AEST (10am AWST).

Zelira Therapeutics Ltd - Three medical cannabis companies in focus at Proactive’s webinar on August 11
The webinar will be live-streamed on the Proactive YouTube channel

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is one of three companies set to present at Proactive's medical cannabis focussed webinar on Tuesday, August 11, along with MGC Pharmaceuticals Ltd (ASX:MXC) and Southern Cannabis Holdings.

The Proactive CEO Investor Sessions is an online variant of the popular conference format the media company has run for over a decade and enables communication between interested investors and some of Australia’s most innovative businesses.

The three companies will outline their plans and focus on the global medical cannabis market, which is expected to grow at a compound annual growth rate (CAGR) of 15.4% from 2019 to 2025, according to Market Research Future (MRFR).

The medical cannabis market is expected to be worth US$52.35 billion by 2025, as per the MRFR report.

Zelira Therapeutics

Zelira Therapeutics is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest growing cannabis markets.

Managing director and CEO Richard Hopkins will talk about the company’s plan to launch its Zenivol™ and HOPE™ range of products into the Australian market by the end of the current quarter.

The developer of clinically validated cannabinoid-derived medicines has entered into the necessary manufacturing and distribution agreements and has also finalised branding and packaging details.

MGC Pharmaceuticals

MGC Pharmaceuticals is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines.

Co-founder and managing director Roby Zomer will outline the company’s progress on its phase II clinical trial in COVID-19 patients at the webinar.

The phase II clinical trial that began in Israel in May 2020 is progressing on schedule.

MGC’s phase II clinical trial at the Mahatma Gandhi Mission’s Medical College & Hospital in India is also moving forward.

Southern Cannabis Holdings

Tim Drury, director and CEO of Southern Cannabis Holdings (SCH), a vertically integrated group of medical cannabis companies based in Sydney, will present at the webinar.

The company builds, integrates and operates high value brands across the cannabis value chain.

SCH companies include Cannabis Access Clinics, Australia’s first and largest network of medicinal cannabis clinics, Applied Cannabis Research, a specialist contract research organisation dedicated to assisting medicinal cannabis companies, and FreshLeaf Analytics, Australia’s leading source of data and information about the medicinal cannabis industry.

Webinar registration

To register for the August 11 webinar, please click here.

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed anytime following the presentation.

For additional information, please contact John Phillips at Proactive on john.phillips@proactiveinvestors.com or call 0431 597 771.

Quick facts: Zelira Therapeutics Ltd


Price: 0.037 AUD

Market Cap: $44.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Zelira Therapeutics and Levin Health talk upcoming chronic pain clinical trial

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCMKTS:ZLDAF) Dr Oludare Odumosu and Levin Health Limited's Mark Brayshaw discuss plans for its upcoming chronic pain clinical trial. Levin will use Zelira's ZTL-106 formulation for testing on retired athletes in a chronic pain treatment study at La Trobe...

on 7/6/21

3 min read